Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
The use of drug combinations has revolutionized the treatment of HIV but there is no equivalent combination product that exists for prevention, particularly for topical HIV prevention. Strategies to combine chemically incompatible agents may facilitate the discovery of unique drug-drug activities, p...
Main Authors: | Thanyanan Chaowanachan, Emily Krogstad, Cameron Ball, Kim A Woodrow |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3632578?pdf=render |
Similar Items
-
Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
by: Jack E Heron, et al.
Published: (2023-01-01) -
HIV antiretroviral preexposure prophylaxis
by: Richard Tjan
Published: (2015-12-01) -
Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
by: Laura Else, et al.
Published: (2022-06-01) -
Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy
by: Mwila Mulubwa, et al.
Published: (2017-12-01) -
Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)